69 results about "Candidal infections" patented technology

The present invention relates to an oral composition which includes an organoleptically suitable carrier and an amount of a terpenoid and a flavonoid, dispersed in the carrier, which is effective to prevent or treat dental caries, dental plaque formation, gingivitis, candidiasis, dental stomatitis, aphthous ulceration, or fungal infection. The invention also relates to various uses of oral compositions, containing a terpenoid, a flavonoid, or both, such uses include: inhibiting the activity of surface-bound glusosyltransferase; treating or inhibiting dental caries, gingivitis, candidiasis, denture stomatitis; inhibiting the accumulation of microorganisms on an oral surface; and/or treating or inhibiting aphthous ulcerations on an oral surface.

A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.

The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract, etc., for inhibiting and preventing the overgrowth of Candida fungus and for treating Candidiasis and its associated symptoms.

Methods and devices for the detection of proteins secreted by the pathogenic growth form of Candida species are disclosed. The disclosed devices may constitute a method for the diagnosis of acute or chronic infections, including candidiasis, caused by microorganisms of the Candida species, such as C. albicans, for example. The devices of the present invention incorporate antibodies specific to lipase proteins whose expression is differentiated upon the conversion of the Candida species from the commensal to the pathogenic form. The antibodies may be used in assays to allow the diagnosis of candidal infections and disease conditions. Either monoclonal antibodies or polyclonal antibodies may be used, and in the case of the monoclonals, the specific epitopes of the LIP protein may be detected as well as the LIP protein itself.

The invention relates to the technical field of antibacterial gel, in particular to chitosan antibacterial gel and a preparation method thereof. Each liter of the chitosan antibacterial gel comprises the following raw materials by weight: 5-30g of modified chitosan, 2.5-10g of carbomer, 1-1.8g of alum, 2-40g of glycerol, 0.3-10g of lactic acid, 0.1-0.8g of menthol and 2-8g of sodium carboxymethylcellulose. The chitosan antibacterial gel which is good in curative effect, can be used for preventing relapse of inflammation and is harmless to human body is prepared by using the synergistic effect of modified chitosan serving as a major raw material as well as carbomer, alum, glycerol, lactic acid and sodium carboxymethylcellulose serving as auxiliary materials, and is suitable for preventing, treating and nursing various vaginal bacterial infections, trichomonas infections, mixed infections, vulvitis, leucorrhea, candidal infection as well as wound infections of cervix uteri, genital tract and mucous membrane. By using the chitosan antibacterial gel, wound healing after physical treatment of cervical erosion is promoted, and nursing of vaginal dryness as well as cross infections in sexual intercourse and the like is improved.

The present invention features a novel use of processed ingredients from the Indian mulberry plant, and particularly a novel use of one or more processed Morinda citrifolia-based naturaceutical formulations comprising one or more of a processed Morinda citrifolia fruit juice, puree juice, oil or oil extract, dietary fiber, alcohol extract, etc., for inhibiting and preventing the overgrowth of Candida fungus and for treating Candidiasis and its associated symptoms.

Actuators for an aerosol inhalation device containing a housing adapted to receive an aerosol canister containing a pressurized medicament formulation, a mouthpiece portion through which the user inhales, a nozzle block and an orifice and a tubular element extending in the mouthpiece portion from the orifice aperture in a longitudinal axis substantially aligned with a longitudinal axis of the mouthpiece portion provide a significant reduction in the non-respirable, coarse fraction of the emitted aerosol medicament via inertial impaction and retention in the actuator than in the oro-pharynx, with consequent less associated side effects and oral candidiasis in the patient. In addition the presence of the tubular element has minimal, negligible impact on the fine particle dose and on the particle size distribution (PSD) of the delivered particles having aerodynamic diameter lower than 9 μm.

A method for preparing optical pure naproxen by lipase chiral resoluted naproxen methoxycarbonyl in water-ionic liquid two-phase system is disclosed. It is carried out by taking lipase cylindrical candidiasis L-1754 as catalyst and taking racemic naproxen methoxycarbonyl as reactive substratum. It achieves three-dimensional selectivity and activity.

The invention provides a method for treating and/or preventing a wide scope of vaginal and vulval infections, such as those caused by bacteria, parasites or yeasts, by administering gallic acid to a subject in need of treatment. A composition containing gallic acid for treating vaginal infections is also disclosed. It has been found that gallic acid is capable of selectively inhibiting the growth of Trichomonas vaginalis, a parasite that causes trichomonas vaginitis; Gardnerella vaginalis, a bacterium that causes bacterial vaginosis; and Candida albicans, a yeast that causes candidiasis and vulvitis; while not inhibiting the growth of Lactobacillus acidophilus, the dominant bacteria in a healthy vaginal ecosystem. Gallic acid is safe and cost-effective, and can be used alone or incorporated into different vaginal health products to treat and/or prevent vaginal infections.

The invention relates to Chinese and western medicament compound cream for preventing and treating onychomycosis infected by candidiasis albrican and a preparation method thereof. The cream is yellow cream formed by evenly dispersing mixture of a Chinese medicament extract and a western medicament in a substrate by use of the action of a mixed emulsifying agent. The cream prepared by the method has the advantages of even dispersed main medicament, even and smooth cream, proper viscosity, as long as easily coating on skin, mucous membrane and wound surface, and meeting the requirement of Chinese pharmacopoeia with controllable quality. Pharmacodynamic research proves that the cream has actions of preventing and treating the onychomycosis infected by Candida albicans, and has assistant treatment action on secondary inflammation because of mycotic infection, such as whitlow.

This invention relates to domain antibodies. In particular, it relates to domain antibodies (dAbs) that recognize virulence traits of Candida spp. and confer passive protection against candidiasis.

The invention discloses application of streptococcus sanguis protein to preparation of drugs inhibiting candida albicans and relates to application of streptococcus sanguis protein on drugs. The problems that azole type and polyenoid type chemical synthesis drugs are large in toxic and side effects in treatment of candidal infection and drug-resistant strain bacteria can be generated easily are solved. The streptococcus sanguis mixed protein is used for preparing the drugs inhibiting the candida albicans. The streptococcus sanguis protein makes the cell morphology of the candida albicans change and the membrane permeability increased, the adhesive effect and the gemmation of the candida albicans are inhibited, and generation of hyphae is interdicted. According to the application, streptococcus sanguis extracts are used for funguses antagonism, and it is verified that the streptococcus sanguis extracts have a high inhibiting effect on funguses.

Provided is the new strain Lactobacillus pentosus CECT 7504 and compositions and products comprising said strain and uses in the prevention and/or treatment of candidiasis (oral, intestinal and vaginal) and of bacterial vaginosis.

Pharmaceutical compositions and methods for treating skin or mucus fungal infections of feet, nails, groin, hands, tongue and other locations are disclosed herein. The pharmaceutical composition disclosed herein comprises at least one triazole agent. Methods of treating tinea pedis, tinea manuum, tinea unguium, tinea cruris, tinea corpora, tinea versicolor, candidiasis, aspergillosis, onychomycosis, coccidiodomycosis, cryptococcal meningitis, histoplasmosis, hoof thrush, hoof rot, tongue and mouth lesions, seborrheic dermatitis, and combinations thereof, are also presently disclosed.

The Xiaomi Huayu Capsule of the present invention is a traditional Chinese medicine capsule preparation for treating inflammatory diseases such as vaginitis, cervicitis, ovariitis, and mastitis. If it is completely cured, when the body is weak and the vaginal environment is suitable, candida and trichomonas are very easy to multiply in large numbers, causing relapses, lingering and repeated, and even prolonged treatment. Traditional Chinese medicine believes that it belongs to the category of "itching of vulva" and "leukorrhagia". It is considered to be caused by deficiency of the spleen to produce dampness, dampness and heat betting, damp accumulation and insects, or exogenous damp pathogens, pathogenic poisons invading, and worms eating into the yin. The pathological properties are deficiency in origin and excess in superficiality, deficiency of the spleen as the foundation, and exogenous pathogenic infection as the standard. Treatment treats both symptoms and root causes. The "Xiaomi Huayu Capsule" of the present invention invigorates the spleen and removes dampness, regulates the whole body, relieves vaginal discharge and restrains dampness, cleans the genitals, kills insects and sterilizes, clears away heat and detoxifies. The present invention directly acts on the body, can obviously regulate the overall function, enhance immunity, resist the invasion of evil poison, improve microcirculation, and promote the absorption of inflammation, so the cure rate is high and the curative effect is good.

The invention discloses a novel application of jatrorrhizine for treating candida albicans infectious diseases. The jatrorrhizine can be extracted from plants of coptis roots, amur corktree barks, caulis mahoniae and the like. The study shows that half bacteriostasis concentration of the jatrorrhizine to candida albicans is 139+/-21mg/L, and effective dose of the jatrorrhizine for enhancing body resistibility of a low immune function mouse to the candida albicans is 30mg/Kg. The jatrorrhizine and pharmaceutically acceptable salts, esters or sugars, excipients and the like are utilized for preparing medicines for treating diseases caused by the fact that the candida albicans infect human and livestock, and the jatrorrhizine can be applied to, but is not limited to, medicines for treating human skins, mucous membranes, internal organs or nervous centralis candidiasis, livestock upper digestive tract mycoses and the like. The jatrorrhizine and the pharmaceutically acceptable salts, esters or sugars and excipients and the like can be prepared to be injection, oral administration and external preparations and dosage forms thereof which are pharmaceutically acceptable such as injections, tablets, capsules, liniments, pastes, smearing agents, emulsions, nanoparticle emulsions, and the like.

The invention discloses a vaginal lotion based on female vaginal nursing. The vaginal lotion is prepared from the following components: tea tree essential oil, radix sophorae flavescentis, cortex phellodendri, fructus cnidii, radix stemonae, cortex dictamni, herba senecionis scandentis and herba menthae. According to the vaginal lotion, the radix sophorae flavescentis, the cortex phellodendri, the fructus cnidii, the radix stemonae, the cortex dictamni and the herba senecionis scandentis, which have functions of clearing away heat and drying dampness, are combined; the components generate synergistic action; the effects of clearing away the heat and drying the dampness are effectively improved; meanwhile, according to the vaginal lotion, the tea tree essential oil which has an antibacterial function is added in a formula; not only can the sterilization function of the formula be improved, but also a better bacteriostatic effect is achieved; the vaginal lotion is particularly has a better inhibition effect on candidiasis albicans.

The disclosure features isolated polypeptides of Hyr1. The disclosure further features vaccines and antibodies useful in treating or preventing candidiasis or Acinetobacter infections or both. Further disclosed are isolated polypeptides consisting of between 14 and 20 amino acids for vaccine preparation. The specific amino acid sequences of isolated polypeptides of Hyr1 are also disclosed.

The protein CAMP65p of C. albicans has been found to be play a significant role in both adhesion and the production of hyphae, which are important factors in both virulence and resistance to clearing. This invention provides antibodies to CAMP65p useful for administration to patients for prophylaxis and treatment of candidal infections.

Provided is artificial saliva including hyaluronic acid (HA). The artificial saliva may be used to treat xerostomia or oral candidiasis and can be effectively used to prevent or treat complications cased by reduced secretion of saliva, since the artificial saliva is in a physiological range of human saliva and shows adequate antimicrobial activities.